Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...
Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases
Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...
Soaring Costs of Cynomolgus Monkeys Impact China’s Biologic Drug Development
Cynomolgus monkeys, or macaques, used in laboratory experiments have seen their value skyrocket due to...
Shanghai Henlius Partners with Organon for Global Biosimilar Commercialization
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) has entered into a licensing and supply agreement...
BeiGene’s Brukinsa Faces Three-Month FDA Approval Delay for CLL/SLL Indication
China-based biotech company BeiGene Inc. (Nasdaq: BGNE) will experience a three-month delay in its pursuit...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...
Innovent Biologics Receives BPOM Approval for Bevagen in Indonesia
China-based Innovent Biologics Inc. (HKG: 1801) has announced receiving indication approvals from Indonesia’s Badan Pengawas...
Innovent Biologics’ IBI306 Accepted for Review by China’s NMPA for Hypercholesterolemia
China-based Innovent Biologics Inc. (HKG: 1801) has announced that a New Drug Application (NDA) filing...
NHSA Releases Draft Proposals for NRDL Annual Renewal Process
The National Healthcare Security Administration (NHSA) has formulated and released draft proposals for rules covering...
Clover Biopharmaceuticals Begins Phase III Trial for COVID-19 Booster SCB-2019
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the immunization of the first group of...
InventisBio’s KRAS G12C Inhibitor D-1553 Earns CDE Breakthrough Therapy Status
China-based InventisBio (Shanghai) Co., Ltd announced receiving breakthrough therapy designation (BTD) status for its KRAS...
CANbridge Pharmaceuticals Presents Positive Phase I Data for CAN106 at EHA Congress
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) released the latest data from a...
Zai Lab’s Repotrectinib Earns Two Breakthrough Therapy Designations in China for ROS1+ NSCLC
China-based biopharma Zai Lab Ltd (NASDAQ: ZLAB) announced receiving two breakthrough therapy designations (BTDs) from...
OnCusp Therapeutics Licenses Multitude’s CDH6 ADC for Global Development
US-based OnCusp Therapeutics has entered into a licensing agreement with China’s Multitude Therapeutics for the...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...
Kangpu Biopharmaceuticals Begins Phase IIa Trial of KPG-818 for Systemic Lupus Erythematosus
Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind,...
Shanghai MicroPort MedBot Completes World’s Furthest Remote Robot Surgery via 5G
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced the successful completion of a remote...
Pfizer’s Lorbrena Receives First Prescription in China for NSCLC Treatment
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the first prescription of its third-generation...
HealZen Therapeutics and Hisun Partner on First-in-Class Protein Degradation Product
Hangzhou-based HealZen Therapeutics Protein Degradation Hisun Pharmaceutical Co., Ltd. a has formed a strategic partnership...
Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma
Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...